XNYS
AORT
Market cap1.03bUSD
Oct 08, Last price
21.21USD
1D
-1.85%
1Q
-11.96%
Jan 2017
10.76%
Name
Artivion Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Related entities
Subsidiaries
JOTEC GmbH
Key people
James Mackin
Chairman of the Board, President, Chief Executive Officer, Director · since 2015
Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Treasurer · since 2025
Jean Holloway
Senior Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary · since 2016
Marshall Stanton
Senior Vice President, Clinical Research and Chief Medical Officer · since 2021
Florian Tyrs
Vice President - Global Operations · since 2023
Matthew Getz
Vice President - Human Resources · since 2019
Andrew Green
Vice President - Regulatory Affairs · since 2021
Amy Horton
Chief Accounting Officer, Vice President · since 2016
Rochelle Maney
Vice President - Global Quality · since 2021
John Davis
Senior Vice President - Global Sales and Marketing · since 2015
Thomas Ackerman
Independent Director · since 2003
Daniel Bevevino
Independent Director · since 2003
Marna Borgstrom
Independent Director · since 2018
James Bullock
Independent Director · since 2016
Elizabeth Hoff
Independent Director · since 2022
Independent Director · since 2012
Anthony Semedo
Independent Director · since 2021
Legal address
C/O COGENCY GLOBAL INC.
850 NEW BURTON ROAD
SUITE 201
DOVER, DE 19904
US
850 NEW BURTON ROAD
SUITE 201
DOVER, DE 19904
US
Headquarters
1655 Roberts Blvd NW
Kennesaw, GA 30144
US
Kennesaw, GA 30144
US
Previous name
CRYOLIFE, INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||